News Artiva announces terms for its second IPO attempt After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.
Oncology Move over CAR-T: The potential of NK cells in cell therapy The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren't the only option for cell th
News Novo Holdings leads $100m round for novel painkiller biotech SiteOne Therapeutics has completed a $100 million third-round financing that will support clinical trials of its non-opioid painkiller.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.